To include your compound in the COVID-19 Resource Center, submit it here.

Rozrolimupab: Final Phase II data

Final data from a dose-escalation, open-label, international Phase II trial in 61 Rhesus D (RhD)-positive, non-splenectomized patients

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE